HIV Mutation Detail Information

Virus Mutation HIV Mutation V182I


Basic Characteristics of Mutations
Mutation Site V182I
Mutation Site Sentence Comparison of gp41 amino acid frequencies between this group and a comparison group of 1221 gp41 sequences from INSTI- naive individuals using Fisher's exact test with Benjamini-Hochberg correction for multiple comparisons identified the gp41 substitution V182I (OR=3.75, p=2.2x10-4, q=0.01) as over-represented among INSTI-treated persons.
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region gp41
Standardized Encoding Gene Env  
Genotype/Subtype -
Viral Reference -
Functional Impact and Mechanisms
Disease HIV Infections    
Immune -
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information -
Treatment INSTI
Location -
Literature Information
PMID 40358920
Title Investigation of Integrase Inhibitor Resistance Mutations in gp41 in Clinical Samples
Author Sudderuddin H,Dang Z,Watson B,Atkinson K,Le A,Sereda P,Brumme ZL,Brumme CJ
Journal Journal of acquired immune deficiency syndromes (1999)
Journal Info 2025 May 13
Abstract BACKGROUND: Mutations conferring resistance to HIV Integrase Strand Transfer Inhibitors (INSTI) can occur outside integrase, including in env gp41, in vitro, but it remains unclear whether these arise under INSTI selection in vivo. METHODS: Using a large database of clinically-derived HIV sequences linked to antiretroviral treatment histories, we sought to identify mutations in gp41 associated with INSTI exposure by comparing integrase and gp41 amino acid frequencies in INSTI-naive versus INSTI-treated individuals. Gp41 was investigated because this region is routinely sequenced to assess fusion inhibitor resistance. RESULTS: We identified 72 individuals with subtype B HIV for whom a genotypic INSTI resistance test performed after >/=3 months of INSTI exposure revealed susceptibility to all INSTIs (HIVdb v8.8; score<15), and for whom plasma INSTI concentrations were detectable by mass spectrometry. Gp41 sequencing was successful for 52 (72%) of these. The median INSTI exposure duration in this group was 20 (Q1-Q3:10-39) months, with raltegravir (>54%), dolutegravir (52%) and elvitegravir (23%) being the most frequently prescribed. Comparison of gp41 amino acid frequencies between this group and a comparison group of 1221 gp41 sequences from INSTI- naive individuals using Fisher's exact test with Benjamini-Hochberg correction for multiple comparisons identified the gp41 substitution V182I (OR=3.75, p=2.2x10-4, q=0.01) as over-represented among INSTI-treated persons. When comparing gp41 sequences pre- and post-INSTI therapy in this group however, no evidence of INSTI-driven selection was observed at this position. CONCLUSION: While off-target INSTI substitutions may arise in vivo, there is currently insufficient evidence to recommend expanding INSTI resistance testing to include Env.
Sequence Data -
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.